A combination of castration with 125I brachtherapy in middle and late period prostate cancer
10.3760/cma.j.issn.1000-6702.2011.06.017
- VernacularTitle:去势联合125I粒子近距离放疗治疗中晚期前列腺癌
- Author:
Haitao WANG
;
Jiwei ZHANG
;
Yan BAI
;
Ming XIA
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
125I brachtherapy;
Castration
- From:
Chinese Journal of Urology
2011;32(6):408-410
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic efficacy of castration with 125I brachtherapy in middle and late stage prostate cancer. Methods Sixty-six patients with prostate cancer from 2004 to 2009 were analyzed, 40 were at clinical stage C and 26 were at clinical stage D, 42 had a pathologic grade G2 and 24 had a pathologic grade G3. The first endocrinal therapy used was total androgen blockade (chemical castration and anti-androgen drugs). The therapeutic time was three months before bilateral orchidectomy and brachtherapy. A 3D radiotherapy planning system was used for brachtherapy with transrectal ultrasound-guided radioactive 125I seed uniform implantation. Follow-up endocrinal therapy was decided according to a monthly check of serum PSA (prostate specific antigen) levels. After six months, serum PSA, IPSS and volume of the prostate before and after treatment were compared. Results The operations were completed successfully in all cases. The mean number of 125I seeds implanted was 55. The mean follow-up was 10 to 62 months, with an average of 49 months. Serum PSA, IPSS and the volume of the prostate was reduced significantly six months after operation (P<0.05). Conclusions Castration with 125I brachtherapy is an effective approach in combination therapy for treating middle and late stage prostate cancer.
